Trends in the Use of IV Iron and ESAs Under the Prospective Payment System: ESRD Commercial and Medicare Populations

StatusFinished
Effective start/end date1/07/1530/06/16

Funding

  • Keryx Biopharmaceuticals, Inc.: $76,500.00

Keywords

  • Chronic Kidney Disease, Health Services Research